Literature DB >> 9179560

Pharmacokinetics of a new oral formulation of amoxicillin.

M H Prevot1, F Jehl, B Rouveix.   

Abstract

The bioavailability of the recently developed 1 g dispersible tablet form of amoxicillin (B) and the 1 g dispersible tablet in suspension form (C) were compared to that of the 1 g standard reference formulation (A). Twelve healthy volunteers were involved in this single-dose, open, randomized, three-way cross-over study. The mean peak serum levels were 14.1 +/- 4.1 micrograms/ml after A, 15.1 +/- 3.1 micrograms/ml after B and 15.1 +/- 5.4 micrograms/ml after C. The area under the drug concentration versus time curves were 47.6 +/- 12.0 micrograms.h/ml after A, 52.8 +/- 10.2 micrograms.h/ml after B and 51.1 +/- 13.8 micrograms.h/ml after C. On the basis of these two pharmacokinetic parameters, the three formulations were found to be bioequivalent. In addition, the predicted serum concentrations during multiple dosing (3 times a day), derived from the corresponding mean concentrations after a single 1 g dose of C showed that 8 hourly administration would yield therapeutic serum concentrations for infections such as uncomplicated community-acquired pneumonia due to susceptible or less susceptible strains in otherwise healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9179560     DOI: 10.1007/BF03189784

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  29 in total

1.  Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.

Authors:  P G Welling; H Huang; P A Koch; W A Craig; P O Madsen
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

2.  Postantibiotic effects.

Authors:  B S Vogelman; W A Craig
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

3.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 4.  Treatment of lower respiratory infections.

Authors:  J T Macfarlane
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

5.  Current practice in penicillin dosing.

Authors:  F Nordbring
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

6.  -amino-p-hydroxybenzylpenicillin (BRL 2333), a new semisynthetic penicillin: absorption and excretion in man.

Authors:  E A Croydon; R Sutherland
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

7.  Bioavailability of new formulations of amoxicillin in relation to its absorption kinetics.

Authors:  W Hespe; J S Verschoor; M Olthoff
Journal:  Arzneimittelforschung       Date:  1987-03

8.  Reappraisal of amoxycillin absorption kinetics.

Authors:  J F Westphal; A Deslandes; J M Brogard; C Carbon
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

9.  Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; P Fontijne; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

10.  Nonlinearity of amoxicillin absorption kinetics in human.

Authors:  G Paintaud; G Alván; M L Dahl; A Grahnén; J Sjövall; J O Svensson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more
  2 in total

1.  Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters.

Authors:  G Suarez-Kurtz; F M Ribeiro; F L Vicente; C J Struchiner
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin. In vivo study in rats.

Authors:  Thales Rocha Mattos Filho; Marcelo de Souza Junqueira; Francisco Carlos Groppo; Rogério Heládio Lopes Motta; Fábio Ferreira Perazzo
Journal:  J Appl Oral Sci       Date:  2006-10       Impact factor: 2.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.